Published in Nature on February 10, 2016
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature (2016) 1.51
Artemisinin Action and Resistance in Plasmodium falciparum. Trends Parasitol (2016) 0.93
Resolution advances in cryo-EM enable application to drug discovery. Curr Opin Struct Biol (2016) 0.90
Unravelling biological macromolecules with cryo-electron microscopy. Nature (2016) 0.89
Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome. ACS Infect Dis (2016) 0.78
The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria. FEBS J (2016) 0.76
Structural Study of Heterogeneous Biological Samples by Cryoelectron Microscopy and Image Processing. Biomed Res Int (2017) 0.75
Antimalarials: Novel proteasome inhibitor combats malaria. Nat Rev Drug Discov (2016) 0.75
Design of Selective Substrates and Activity-Based Probes for Hydrolase Important for Pathogenesis 1 (HIP1) from Mycobacterium tuberculosis. ACS Infect Dis (2016) 0.75
Proteases as Antimalarial Targets: Strategies for Genetic, Chemical, and Therapeutic Validation. FEBS J (2017) 0.75
Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni. PLoS One (2017) 0.75
Development of a potent inhibitor of the Plasmodium proteasome with reduced mammalian toxicity. J Med Chem (2017) 0.75
Tools for the Cryo-EM Gold Rush: Going from the cryo-EM map to the atomistic model. Biosci Rep (2017) 0.75
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Features and development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 89.46
MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2009) 53.36
SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol (1996) 22.89
Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J Mol Biol (2003) 12.04
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr (2012) 11.31
The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem (1999) 8.97
The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc (2015) 8.53
Flexible fitting of atomic structures into electron microscopy maps using molecular dynamics. Structure (2008) 5.97
Quantifying the local resolution of cryo-EM density maps. Nat Methods (2013) 4.36
Improved visualization of protein consensus sequences by iceLogo. Nat Methods (2009) 3.64
Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science (2014) 3.41
Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum. Nat Chem Biol (2008) 3.16
Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol (2002) 2.91
Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A (1997) 2.81
Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem (1995) 2.70
A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature (2015) 2.64
Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26
Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother (1998) 2.07
Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science (2014) 2.02
Semi-automated selection of cryo-EM particles in RELION-1.3. J Struct Biol (2014) 1.68
Marine actinomycetes: a new source of compounds against the human malaria parasite. PLoS One (2008) 1.67
Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol (2015) 1.67
Proteasome activators. Mol Cell (2011) 1.62
Assembly, structure, and function of the 26S proteasome. Trends Cell Biol (2010) 1.61
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem (2009) 1.50
Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol (2009) 1.47
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity. Antimicrob Agents Chemother (2009) 1.32
Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malar J (2008) 1.27
Substrate specificity of the human proteasome. Chem Biol (2001) 1.19
Global identification of peptidase specificity by multiplex substrate profiling. Nat Methods (2012) 1.14
Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol (2012) 1.09
The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention? Int J Parasitol Drugs Drug Resist (2012) 1.06
Crystal structure of the human 20S proteasome in complex with carfilzomib. Structure (2015) 1.05
Assessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probes. ACS Chem Biol (2014) 0.90
Destructin-1 is a collagen-degrading endopeptidase secreted by Pseudogymnoascus destructans, the causative agent of white-nose syndrome. Proc Natl Acad Sci U S A (2015) 0.89
Identification of potent and selective non-covalent inhibitors of the Plasmodium falciparum proteasome. J Am Chem Soc (2014) 0.86
Cryo-EM reveals the conformation of a substrate analogue in the human 20S proteasome core. Nat Commun (2015) 0.86
Blocking Plasmodium falciparum development via dual inhibition of hemoglobin degradation and the ubiquitin proteasome system by MG132. PLoS One (2013) 0.84